Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
Background. The 5-year survival rate of patients with metastatic gastric cancer (GC) is only 5%. However, trials have demonstrated promising antitumor activity for targeted therapies/immunotherapies among chemorefractory metastatic GC patients. Pembrolizumab has shown particular efficacy among patie...
Main Authors: | Brianna Lauren, Sassan Ostvar, Elisabeth Silver, Myles Ingram, Aaron Oh, Lindsay Kumble, Monika Laszkowska, Jacqueline N. Chu, Dawn L. Hershman, Gulam Manji, Alfred I. Neugut, Chin Hur |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2020/2198960 |
Similar Items
-
Deep Reinforcement Learning for Optimal Critical Care Pain Management with Morphine using Dueling Double-Deep Q Networks
by: Lopez-Martinez, Daniel, et al.
Published: (2021) -
Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma
by: Monika Laszkowska, et al.
Published: (2020-08-01) -
Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model
by: Judith Kim, et al.
Published: (2021-01-01) -
Acute mechanical stress in primary porcine RPE cells induces angiogenic factor expression and in vitro angiogenesis
by: Farhad Farjood, et al.
Published: (2020-04-01) -
Prediction of COVID-19 Social Distancing Adherence (SoDA) on the United States county-level
by: Myles Ingram, et al.
Published: (2021-03-01)